Lawrence S. Olanoff, M.D., Ph.D.
Dr. Olanoff is Special Advisor to the President for Corporate Relations at MUSC. After a long career in the pharmaceutical industry, he retired from his last position as President and Chief Operating Officer (2006-2010) at Forest Laboratories, Inc., and served as a Director of Forest Laboratories, Inc. until 2014. He is currently a Board member at Ironwood Pharmaceuticals Inc. and Axovant Sciences Ltd. He also serves as a member of the non-profit Boards of the Institute for Applied Neurosciences at the Medical University of SC, the Clinical Biotechnology and Research Institute at Roper St. Francis Hospitals and the Horizon Development Project; is a member of the Advisory Board of BioMotiv and is an ex-officio member of the MUSC Foundation for Research Development Board. In these affiliations, he is actively involved in advising companies and non-profit institutions in areas of drug discovery and development.
Dr. Olanoff was President and Chief Executive Officer of Celsion Corporation from 2005 to 2006. From 1995 until 2005, Dr. Olanoff was responsible for the leadership of research and development activities for Forest Laboratories, Inc., ultimately as its Executive Vice President-Scientific Affairs. From 1993 to 1995, Dr. Olanoff was Senior Vice President-Clinical Research and Development at Sandoz Pharmaceutical Corporation. From 1984 to 1993, Dr. Olanoff was employed by The Upjohn Company, where his last position was Corporate Vice President-Clinical Development and Medical Affairs.
Dr. Olanoff holds MD and PhD (Biomedical Engineering) degrees from Case Western Reserve University and was a medical resident and clinical pharmacology fellow at MUSC. He is the author or co-author of numerous scientific publications in the fields of clinical pharmacology, drug delivery and pharmacokinetics. During his industry career, he was involved in the approval of some 30 new drugs, new indications or novel formulations in the US.